aclarubicin/cáncer

El enlace se guarda en el portapapeles.

Elija el tipo de clasificación

Página 1 desde 90 resultados

Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

The effect of combinations of the anthracyclines aclarubicin and daunorubicin was investigated in a clonogenic assay using the human small cell lung cancer cell line OC-NYH and a multidrug-resistant (MDR) murine subline of Ehrlich ascites tumor (EHR2/DNR+). It was found that the cytotoxicity of

Management of malignant pericardial effusion resulting from recurrent cancer with local instillation of aclarubicin hydrochloride.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

To determine the efficacy of aclarubicin hydrochloride in local control of malignant pericardial effusion, the authors carried out a trial of pericardial drainage with local administration of this agent in five patients, whose effusions had produced cardiac tamponade. All patients were women, and

[Combination chemotherapy with aclarubicin and cisplatinum against malignant intracranial tumor--an in vitro study].

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Augmentation of cytotoxicity against cultured human tumor cell lines (5 gliomas, 2 neuroblastomas, 2 sarcomas) using a combination of Aclarubicin (ACR) and Cisplatinum (CDDP) was analysed in vitro from the viewpoints of cell growth inhibition and alteration of the DNA histogram. Synergistic effects

An in vivo and in vitro trial of aclarubicin in metastatic breast cancer: a novel approach to the study of analogs.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Aclarubicin is an anthracycline antibiotic that differs from doxorubicin in its structure, mechanism of action, and preclinical toxicity profile, especially its reduced cardiotoxicity. We therefore conducted a side-by-side in vivo and in vitro trial of this agent in metastatic breast-cancer patients

[Combination chemotherapy of ovarian cancer with cisplatinum, aclarubicin and tegafur].

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Two hundred fifty-nine patients with ovarian cancers were treated with the combination of CDDP, aclarubicin and tegafur. Ninety-seven of them had macroscopic diseases during the combination chemotherapy, and the overall anti-tumor response rate (CR + PR) for these patients was 54.6%. It was 60.0%

Enhanced anti-cancer effects of intralymphatic aclarubicin on distal lymph node metastases: quantitative evaluation using a new experimental model in mice.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

The anti-cancer drug aclarubicin (2.0 mg/kg body weight) was injected into the left popliteal lymph node (the primary draining node of the foot-pad region) or into the tail vein, 8 days after a subcutaneous inoculation of 5 x 10(5) P388 leukemia cells/mouse in the left hind paw foot-pad of mouse

Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Anthracycline drugs are potent anti-tumor agents. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a death ligand with promising anti-cancer effects. However, some tumor types develop resistance to TRAIL. We examined the effect of aclarubicin (ACR), an anthracycline, in combination

Aclarubicin in advanced thyroid cancer: a phase II study.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Twenty-four patients with metastatic thyroid cancer were treated with aclarubicin intravenously at a dose of 25-30 mg/m2 daily for 4 days and treatment was repeated every 3 weeks. None of the patients had previously received chemotherapy. Twenty-three patients received two or more treatment cycles

Aclarubicin, an anthracycline anti-cancer drug, fluorescently contrasts mitochondria and reduces the oxygen consumption rate in living human cells.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Aclarubicin (Acla), an effective anthracycline chemotherapeutic agent for hematologic cancers and solid tumors, is documented to perturb chromatin function via histone eviction and DNA topoisomerase inhibition in the nucleus, but much less attention has been paid to cytotoxic function in the

Experimental and clinical studies on aclarubicin in the treatment of solid tumors.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Experimental and clinical studies were performed on aclarubicin in the treatment of solid tumors. In experimental cancer chemotherapy using human tumor xenografts transplanted to nude mice, aclarubicin showed a moderate antitumor effect (retardation of tumor growth) and nearly the same spectrum of

[Metastatic thyroid cancer: sudden death following aclarubicin therapy].

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

We report on a 62-year-old patient with a metastasising, only poorly differentiated follicular thyroid carcinoma, who was subjected postoperatively to chemotherapy with Aclarubicin. Aclarubicin (Aclaplastin) is a new cytostatic agent, from the group of anthracyclines, with fewer side effects and

[The effect of combined chemotherapy with UFT, cis-platinum and aclarubicin in metastatic brain tumors].

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Thirteen patients with metastatic brain tumors were treated with two different chemotherapy regimens. Six patients were treated with three antitumor drugs, UFT, CDDP and ACR (Group A) and the other seven patients were treated with two antitumor drugs, CDDP and ACR (Group B). Initial response to each

Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

The effect of combinations of the anthracycline aclarubicin and the topoisomerase II targeting drugs 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyra noside) (VP-16) and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) was investigated in a clonogenic assay. The cytotoxicity

Phase II study of aclarubicin in previously untreated patients with advanced soft tissue sarcoma: a Southeastern Cancer Study Group trial.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Aclarubicin: a new drug in cancer treatment. Proceedings of a satellite symposium. June 17th, 1985, Stockholm.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Únete a nuestra
página de facebook

Herbal & Natural Medicine

La base de datos de hierbas medicinales más completa respaldada por la ciencia

Funciona en 55 idiomas
Curas a base de hierbas respaldadas por la ciencia
Reconocimiento de hierbas por imagen
Mapa GPS interactivo: etiquete hierbas en la ubicación (próximamente)
Leer publicaciones científicas relacionadas con su búsqueda
Buscar hierbas medicinales por sus efectos.
Organice sus intereses y manténgase al día con las noticias de investigación, ensayos clínicos y patentes.

Escriba un síntoma o una enfermedad y lea acerca de las hierbas que podrían ayudar, escriba una hierba y vea las enfermedades y los síntomas contra los que se usa.
* Toda la información se basa en investigaciones científicas publicadas.